公开(公告)号：US5730954A

公开(公告)日：1998-03-24

申请号：US322966

申请日：1994-10-13

申请人： Celal Albayrak ,  Georg Rossling ,  Johannes Tack

发明人： Celal Albayrak ,  Georg Rossling ,  Johannes Tack

IPC分类号： A61K49/18 ,  A61K49/22 ,  A61K49/00 ,  G01N31/00 ,  G01N33/48

CPC分类号： B82Y5/00 ,  A61K49/18 ,  A61K49/228

摘要： A method of using cavitate- or clathrate-forming host/guest complexes for the preparation of contrast media in ultrasonic examination is provided. The host/guest complexes have a host which dissolves in a liquid carrier, releasing the guest (inert gas). With such contrast media, it is possible to diagnose blood and its flow conditions in the heart, and other organs, such as the myocardium, liver, spleen, and kidneys. Other internal systems such as the urinary ducts, the gastrointestinal tract, joints, and eyes can also be imaged.

摘要翻译： 提供了一种在超声检查中使用空化或笼形物形成宿主/客体复合物制备造影剂的方法。 主体/客体配合物具有溶解在液体载体中的主体，释放客体（惰性气体）。 使用这样的造影剂，可以诊断心脏和其他器官如心肌，肝脏，脾脏和肾脏中的血液及其流动状况。 其他内部系统，例如尿管，胃肠道，关节和眼睛也可以成像。

公开(公告)号：US06572894B2

公开(公告)日：2003-06-03

申请号：US09886504

申请日：2001-06-21

申请人： Georg Rössling ,  Celal Albayrak ,  Johannes Tack ,  Reinhard Schmitz

发明人： Georg Rössling ,  Celal Albayrak ,  Johannes Tack ,  Reinhard Schmitz

IPC分类号： A61K948

CPC分类号： A61K9/1647 ,  A61K9/5031 ,  A61K38/09 ,  A61K38/21 ,  A61K38/28 ,  A61K38/38 ,  B01J13/02 ,  Y10S514/937

摘要： The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter ≦8 &mgr;m. According to the invention, biodegradable polymers are dissolved in a halogen-free solvent or solvent mixture, and the buffered active ingredient solution, which has a pH of between 6.0 to 8.0, is dispersed into this solution. Then, an aqueous solution that contains a surfactant (W/O/W-emulsion) is added to this W/O-emulsion, and the solvent is removed. The microcapsules that are produced with this process do not show any tendency toward agglomeration. The encapsulation efficiency of the process is approximately 90 to 95%.

摘要翻译： 本发明涉及一种生产含有肽，蛋白质或其它水溶性生物活性物质作为活性成分的形态上均匀的微胶囊的方法，以及根据该方法制备的微胶囊，其浓度为3至30 重量％，直径<= 8um。 根据本发明，将可生物降解的聚合物溶解在无卤素的溶剂或溶剂混合物中，将pH为6.0-8.0的缓冲活性成分溶液分散在该溶液中。 然后，向该W / O乳液中添加含有表面活性剂（W / O / W-乳液）的水溶液，除去溶剂。 用该方法生产的微胶囊不显示任何凝聚的倾向。 该方法的包封效率约为90至95％。

公开(公告)号：US06294204B1

公开(公告)日：2001-09-25

申请号：US09068471

申请日：1998-09-25

申请人： Georg Rössling ,  Celal Albayrak ,  Johannes Tack ,  Reinhard Schmitz

发明人： Georg Rössling ,  Celal Albayrak ,  Johannes Tack ,  Reinhard Schmitz

IPC分类号： A61K948

CPC分类号： A61K9/1647 ,  A61K9/5031 ,  A61K38/09 ,  A61K38/21 ,  A61K38/28 ,  A61K38/38 ,  B01J13/02 ,  Y10S514/937

摘要： The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter≦8 &mgr;m. According to the invention, biodegradable polymers are dissolved in a halogen-free solvent or solvent mixture, and the buffered active ingredient solution, which has a pH of between 6.0 to 8.0, is dispersed into this solution. Then, an aqueous solution that contains a surface-active substance (W/O/W-emulsion) is added to this W/O-emulsion, and the solvent is removed. The microcapsules that are produced with this process do not show any tendency toward agglomeration. The encapsulation efficiency of the process is approximately 90 to 95%.

摘要翻译： 本发明涉及一种生产含有肽，蛋白质或其它水溶性生物活性物质作为活性成分的形态上均匀的微胶囊的方法，以及根据该方法制备的微胶囊，其浓度为3至30 重量％，直径<=8μm。根据本发明，将可生物降解的聚合物溶解在无卤素溶剂或溶剂混合物中，将pH为6.0-8.0的缓冲活性成分溶液分散在 这个解决方案。 然后，向该W / O乳液中添加含有表面活性物质（W / O / W-乳液）的水溶液，除去溶剂。用该方法制造的微胶囊不显示任何趋势 聚集。 该方法的包封效率约为90至95％。

公开(公告)号：US20070134309A1

公开(公告)日：2007-06-14

申请号：US10570262

申请日：2004-05-30

申请人： Reinhard Horowski ,  Johannes Tack ,  Katalin Bostedt ,  Dirk Schenk

发明人： Reinhard Horowski ,  Johannes Tack ,  Katalin Bostedt ,  Dirk Schenk

IPC分类号： A61K9/70

CPC分类号： A61K9/7061 ,  A61K31/48 ,  A61K47/10

摘要： The invention relates to a transdermal therapeutic system containing ergolin compounds, preferably lisuride, in which the ergolin compound is stabilized. The oxidation-sensitive ergolin compound is stabilized by a combination of at least one liposoluble, free radical-scavenging antioxidant, preferably di-tert.-butyl methyl phenol, di-tert.-butyl metoxy phenol, tocopherol or ubiquinone and a basic polymer.

摘要翻译： 本发明涉及一种含有麦角蛋白化合物，优选碘化镧的透皮治疗系统，其中麦角蛋白化合物稳定化。 氧化敏感的麦角蛋白化合物通过至少一种脂溶性自由基清除抗氧化剂，优选二叔丁基甲基苯酚，二叔丁基甲氧基苯酚，生育酚或泛醌和碱性聚合物的组合来稳定。

公开(公告)号：US5286494A

公开(公告)日：1994-02-15

申请号：US715699

申请日：1991-06-17

申请人： Christian Fechner ,  Michael Humpel ,  Fred Windt-Hanke ,  Johannes Tack

发明人： Christian Fechner ,  Michael Humpel ,  Fred Windt-Hanke ,  Johannes Tack

IPC分类号： A61K9/50 ,  A61K9/54 ,  A61K9/16

CPC分类号： A61K9/5078 ,  A61K9/5026 ,  Y10S514/822

摘要： Medicinal agents are claimed exhibiting sustained release of active compound, containing a solid active ingredient, poorly soluble in water, and auxiliary agents, characterized in that the active compound, in a microcrystalline form or in form of a molecular dispersion, is distributed in or on pellets, and that the pellets are covered by a membrane having retarded permeability with respect to the active compound.

摘要翻译： 药物剂要求显示持续释放的活性化合物，其含有固体活性成分，难溶于水和辅助剂，其特征在于微晶形式或分子分散体形式的活性化合物分布在 颗粒，并且颗粒被相对于活性化合物具有延迟渗透性的膜覆盖。

公开(公告)号：US09695173B2

公开(公告)日：2017-07-04

申请号：US13354832

申请日：2012-01-20

申请人： Rudolf Reiter ,  Johannes Tack ,  Reinhard Horowski

发明人： Rudolf Reiter ,  Johannes Tack ,  Reinhard Horowski

IPC分类号： A61K31/519 ,  C07D471/06 ,  A61K31/00 ,  A61K31/48

CPC分类号： C07D471/06 ,  A61K31/00 ,  A61K31/48

摘要： The present invention relates to the use of ergot derivatives or ergolines, and in particular of lisuride and terguride for the prophylaxis and treatment of constrictive capillary arteriopathy. Constrictive capillary arteriopathy refers to the diseases pulmonary arterial hypertension, endogenously induced or exogenously induced glomerulosclerosis as well as secondary Raynaud's syndrome.

公开(公告)号：US07087078B2

公开(公告)日：2006-08-08

申请号：US10432156

申请日：2001-11-21

申请人： Gesine Hildebrand ,  Johannes Tack ,  Helmut Kaeufer ,  Hans-Martin Wache ,  Thomas Mueller ,  Peter Ewert

发明人： Gesine Hildebrand ,  Johannes Tack ,  Helmut Kaeufer ,  Hans-Martin Wache ,  Thomas Mueller ,  Peter Ewert

IPC分类号： A61F2/06

CPC分类号： A61L31/14 ,  A61L31/06 ,  A61L2400/16 ,  C08L75/04

摘要： New tubular vascular implants (stents) that consist of biocompatible, thermoplastic material that have a shape memory and that contain at least one active ingredient are described. In addition, a process for their production and their use as vascular implants for prophylaxis of restenosis are described.

摘要翻译： 描述了由具有形状记忆并且含有至少一种活性成分的生物相容的热塑性材料组成的新的管状血管植入物（支架）。 此外，描述了其生产方法及其作为用于预防再狭窄的血管植入物的用途。

公开(公告)号：US20060105030A1

公开(公告)日：2006-05-18

申请号：US11087754

申请日：2005-03-24

申请人： Fred Windt-Hanke ,  Clemens Gunther ,  Reinhard Horowski ,  Johannes Tack ,  Adalbert Engfer ,  Katalin Bostedt ,  Dirk Schenk

发明人： Fred Windt-Hanke ,  Clemens Gunther ,  Reinhard Horowski ,  Johannes Tack ,  Adalbert Engfer ,  Katalin Bostedt ,  Dirk Schenk

IPC分类号： A61K9/70

CPC分类号： A61K9/7061 ,  A61K9/7053 ,  A61K31/48

摘要： The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the Restless Leg Syndrome and Periodic Limb Movement Disorder. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

公开(公告)号：US20140058108A1

公开(公告)日：2014-02-27

申请号：US13885058

申请日：2011-11-04

申请人： Reinhard Horowski ,  Heinz Palla ,  Johannes Tack

发明人： Reinhard Horowski ,  Heinz Palla ,  Johannes Tack

IPC分类号： C07D457/12

CPC分类号： A61K31/437 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/19 ,  A61K9/7061 ,  A61K31/48 ,  A61K45/06 ,  C07D457/12 ,  A61K2300/00

摘要： The present invention relates to the use of 5-HT2 receptor antagonists and in particular of 8-α-ergolines such as lisuride, terguride and the derivatives thereof as 5-HT2B and 5-HT2A receptor antagonists and antioxidants in preferably higher-dosed and preferably continuous use for the treatment, progression prophylaxis and general prophylaxis of organ fibroses and other pathological organ remodeling caused by mesenchymal proliferation

摘要翻译： 本发明涉及5-HT2受体拮抗剂，特别是8-α-麦角碱如碲化物，禾草灵及其衍生物作为5-HT2B和5-HT2A受体拮抗剂和抗氧化剂在优选更高剂量和优选地 连续用于治疗，进展预防和器官纤维化的一般预防以及由间充质细胞增殖引起的其他病理性器官重建

公开(公告)号：US20140045879A1

公开(公告)日：2014-02-13

申请号：US13354832

申请日：2012-01-20

申请人： Rudolf Reiter ,  Johannes Tack ,  Reinhard Horowski

发明人： Rudolf Reiter ,  Johannes Tack ,  Reinhard Horowski

IPC分类号： C07D471/06

CPC分类号： C07D471/06 ,  A61K31/00 ,  A61K31/48

摘要： The present invention relates to the use of ergot derivatives or ergolines, and in particular of lisuride and terguride for the prophylaxis and treatment of constrictive capillary arteriopathy. Constrictive capillary arteriopathy refers to the diseases pulmonary arterial hypertension, endogenously induced or exogenously induced glomeruloscleroses as well as secondary Raynaud's syndrome.

摘要翻译： 本发明涉及麦角衍生物或麦角蛋白，特别是利鲁司特和替麦格德用于预防和治疗缩窄性毛细血管病变的用途。 狭窄性毛细血管动脉病是指肺动脉高压，内源诱导或外源性诱导的肾小球硬化以及继发性雷诺综合征的疾病。